Shmeylan Al Harbi

Treatment of Middle East Respiratory Syndrome with a combination of lopinavir-ritonavir and interferon-β1b (MIRACLE trial): study protocol for a randomized controlled trial

Yaseen M. Arabi, Adel Alothman, Hanan H. Balkhy et al. · Trials · 2018 · 261 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +16

Treatment of Middle East respiratory syndrome with a combination of lopinavir/ritonavir and interferon-β1b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial

Yaseen M. Arabi, Ayed Y. Asiri, Abdullah M. Assiri et al. · Trials · 2020 · 132 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +17

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

Yaseen M. Arabi, Ayed Y. Asiri, Abdullah M. Assiri et al. · New England Journal of Medicine · 2020 · 80 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Clinical features and outcomes of critically ill patients with coronavirus disease 2019 (COVID-19): A multicenter cohort study

Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Eljaaly et al. · International Journal of Infectious Diseases · 2021 · 62 citations · Full text

Medicine, Infectious Diseases, Internal Medicine +13

Ascorbic acid as an adjunctive therapy in critically ill patients with COVID-19: a propensity score matched study

Khalid Al Sulaiman, Ohoud Aljuhani, Khalid Bin Saleh et al. · Scientific Reports · 2021 · 53 citations · Full text

Medicine, Pharmacotherapy, Acute Care Medicine +10